GlaxoSmithKline Canada, a subsidiary of UK-based pharmaceuticals company GlaxoSmithKline (GSK), plans to invest $28 million to further strengthen the company’s manufacturing facility in Ontario.
The funds will enable facility improvements, equipment purchases, and enhanced manufacturing capabilities.
GSK’s Mississauga facility will also soon begin producing Voltaren, a consumer health brand in Canada for pain relief.
The investment is part of Mississauga’s economic development strategy to expand its economic development agenda, remain competitive, measure success, and attract innovative businesses to the city.